



Keeping Pace With Evolving Treatment Paradigms in Advanced Renal Cell Carcinoma: The Nurse's View

1.0
NCPD

Chair: Laura S. Wood, RN, MSN, OCN®

Meetings Scheduled: November 1, 2020 – November 15, 2021

- 1.0 NCPD credit
- Pharmacotherapy credit
- ILNA points

Virtual Visiting Faculty Meeting

STATEMENT OF NEED

Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases.

TARGET AUDIENCE

Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with RCC

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

- Distinguish the mechanisms of action of IO agents and VEGFR TKIs in advanced RCC
- Differentiate the efficacy and safety profiles of IO and VEGFR TKI therapies for advanced RCC
- Assess strategies to improve treatment tolerability, control adverse events, and ensure the provision of patient-centered RCC care

Learning objectives apply to all professions in the target audience. There are no prerequisites for this activity.

FACULTY

Laura S. Wood, RN, MSN, OCN® (Chairperson)
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Center

Virginia Seery, MSN, RN, ANP-BC, AOCNP® (Speaker)
Nurse Practitioner
Beth Israel Deaconess Medical Center

Colleen Lewis, NP
Director of Clinical Operations
Phase I Clinical Trials Program
Winship Cancer Institute
Emory University

Nazy Zomorodian, RNC, MSN, CUNP, CCRC
Urology Nurse Practitioner
Director of GU Clinical Trials
UCLA Medical Center

ABOUT THE SPEAKER

Virginia Seery, MSN, RN, ANP-BC, AOCNP®, is a nurse practitioner in the Biologics and Cutaneous Oncology Programs at Beth Israel Deaconess Medical Center in Boston, where she also serves as Clinical Director of the Immunotherapy Toxicity Clinic. Ms. Seery specializes in the treatment of patients with renal cell carcinoma and melanoma. She serves as a member of the Melanoma Nursing Initiative board, the Kidney Cancer Association clinical advisory board, and the American Society of Clinical Oncology (ASCO) Cancer.Net Melanoma advisory panel. Ms. Seery has authored or coauthored numerous publications focused on the optimal treatment and management of patients with melanoma and RCC.

ACCREDITATION

Provided by



i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.

REGISTRATION

There is no fee to participate in or claim NCPD credit for this activity.

Please note that i3 Health does not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS

i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of an NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

Faculty

- Laura S. Wood, RN, MSN, OCN® discloses that she has served on the speakers' bureau for Bristol Myers Squibb and Merck. She has also served as a consultant for Eisai
- Virginia Seery, MSN, RN, ANP-BC, AOCNP®, discloses that she has served on an advisory board or panel for Exelixis. She has also served as a consultant for Apricity Health
- Colleen Lewis, NP, discloses that she has served on the speakers' bureau for Genentech
- Nazy Zomoridian, RNC, MSN, CUNP, CCRC, has no relevant financial relationships to disclose

Planners and Managers

The i3 Health planners, reviewers, and managers have nothing to disclose.

REQUIREMENTS FOR CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for nursing continuing professional development and is not intended to

promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

AGENDA

- I. Pre-Activity Assessment
- II. Advanced RCC: Overview, Molecular Diagnosis, and Risk Stratification
- III. Case Icebreaker: Tailoring Supportive Care Strategies to Individual Patients
- IV. Mechanisms of Action of IO Agents and VEGFR TKIs
- V. Overview of New Data and Evolving Treatment Paradigms
 - a. IO/IO combinations
 - b. IO/VEGFR TKI combinations
 - c. VEGFR TKI monotherapy
- VI. Assessing and Managing Treatment-Related Adverse Events
- VII. Case Icebreaker: Ensuring Patient-Centered Care Through Multiple Lines of Therapy
- VIII. Future Directions in the Management of Advanced RCC
- IX. Key Learning Takeaways/Faculty Q&As
- X. Post-Activity Assessment
- XI. 4-Week Clinical Pearls Follow-Up Email

DISCLAIMER

The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

SUNSHINE ACT

Per the Physician Payments Sunshine Act, i3 Health is required by law to report to CMS any transfers of value (including food and beverage) provided to a covered recipient during a commercially supported educational event. Effective January 1, 2020, Physician Assistants, Nurse Practitioners, and Clinical Nurse Specialists are considered "covered recipients". All NPs and CNSs who would like to participate in the provided meal will be asked to provide all required information for reporting purposes.

COMMERCIAL SUPPORT

This educational activity is supported by a medical education grant from Exelixis.

Aggregate participant data will be shared with commercial supporters of this activity.

DOWNLOAD THE SPEAKER SLIDES

<https://www.slideshare.net/i3health/keeping-pace-with-evolving-treatment-paradigms-in-advanced-renal-cell-carcinoma-the-nurses-view>

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact i3 Health prior to the live event at 973-928-8085 or support@i3Health.com.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3Health.com.